GLP1_NEW
Tern60 po
TERN60_PO
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.21 (0.25 to 104) | 0.32 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.80 (0.78 to 35.38) | 0.34 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.26 (3.06 to 30.51) | 0.18 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 23.54 (3.17 to 473) | 0.15 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.72 (0.44 to 10.78) | 0.52 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.82 (0.80 to 33.54) | 0.28 |